
⸺ Synova Research
Long-acting amylin analogue researched for appetite regulation and weight management, often paired with GLP-1 agonists in metabolic studies.
Website checkout coming soon — for now, orders are placed directly via our Telegram. Fast replies & secure payment links.
Independently tested
COA on request
Next-day UK dispatch
Order before 2pm
Research use only
Not for human consumption
⸺ Important
⸺ Overview
Cagrilintide is a synthetic long-acting analogue of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Researchers investigate it for satiety signalling, slowed gastric emptying and combined effects when paired with GLP-1 receptor agonists such as Semaglutide or Retatrutide.
⸺ Mechanism of Action
Cagrilintide acts on amylin and calcitonin receptors in the central nervous system, modulating satiety and gastric motility. In animal studies, this produces reduced food intake and changes in body composition, with additive effects observed alongside incretin agonists.
⸺ Research
Rodent studies demonstrate reduced food intake via central amylin-receptor pathways, with effects sustained over chronic dosing.
Preclinical work pairing Cagrilintide with GLP-1 receptor agonists reports additive effects on body weight and glycaemic markers.
Animal models show slower gastric emptying, supporting hypotheses around prolonged satiety following meals.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details

Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.

Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.

Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.